Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Biological DMARDs in Elderly RA Patients: Use, Maintenance & Discontinuation

Natasha Yetman  |  June 17, 2019

A study comparing seven biologic DMARDs in RA patients aged 65 years and older found abatacept had the highest retention rate and the lowest discontinuation rate…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptadalimumabbiologic disease-modifying antirheumatic drugsbiologic DMARDsCertolizumab PegoletanerceptGolimumabinfliximabRheumatoid Arthritis (RA)tocilizumab

Beyond Addiction: Medical Therapy for Addiction May Benefit Medical Adherence

Thomas R. Collins  |  June 17, 2019

Treating patients with rheumatic disease for their addictions will also encourage patients to address their overall health conditions, resulting in better medical adherence…

Filed under:Conditions Tagged with:Addictionaddiction treatmentOpioid abuseOpioids

Risk Assessment & Treatment in APS Patients

Thomas R. Collins  |  June 12, 2019

The pathogenesis of antiphospholipid syndrome (APS) is complicated and may involve local inflammation, vasculopathy, pregnancy complications and thrombosis. During the 2019 ACR State-of-the-Art Clinical Symposium, Lisa Sammaritano, MD, addressed the risk assessment and treatment of APS patients…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:2019 State-of-the-Art Clinical SymposiumAntiphospholipid Antibody Syndrome (APS)Hughes Syndromeriskrisk assessmentthrombosis

Vaccines & Rheumatology Patients

Thomas R. Collins  |  June 12, 2019

Vaccines are often safe for rheumatology patients, but precautions may be needed, said Brian Schwartz, MD, at the 2019 ACR State-of-the-Art Clinical Symposium…

Filed under:Conditions Tagged with:2019 State-of-the-Art Clinical Symposiumpatient carevaccinationvaccines

A Bridge Between Patients & Rheumatologists: What Social Workers Want Rheumatologists to Know

Linda Childers  |  June 4, 2019

An integral part of the rheumatology care team, social workers can address specific issues related to a patient’s overall wellbeing. Here are some insights into how rheumatologists can better partner with social workers as part of the interdisciplinary team to ensure better patient outcomes…

Filed under:Practice Support Tagged with:Association of Rheumatology Professionals (ARP)Care Teamhealthcare teammultidisciplinary care teampatient caresocial worker

Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes

Michele B. Kaufman, PharmD, BCGP  |  June 4, 2019

In a 24-month clinical trial, tofacitinib proved safe and effective in combination with methotrexate in adult patients with RA…

Filed under:Drug Updates Tagged with:MethotrexateRheumatoid Arthritis (RA)Tofacitinib

FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications

Michele B. Kaufman, PharmD, BCGP  |  May 29, 2019

The FDA has approved rizankixumab to treat adults with plaque psoriasis and added boxed warnings to sleep medications…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAplaque psoriasisrizankixumabSleepU.S. Food and Drug Administration (FDA)

Peripheral Manifestations of Spondyloarthritis

Lara C. Pullen, PhD  |  May 29, 2019

A recent study evaluated the factors associated with the presence of peripheral manifestations of spondyloarthritis (SpA), which affects more than half of patients with SpA. Researchers found that being older, HLAB27 negative and having a history of psoriasis were associated with these symptoms…

Filed under:Axial SpondyloarthritisConditions Tagged with:peripheral arthritisperipheral spondyloarthritis

Dr. Sou-Pan Wu Is the First Recipient of the Norman B. Gaylis Research Award

Kimberly Retzlaff  |  May 29, 2019

The Norman B. Gaylis, MD, Research Award for Rheumatologists in Community Practice is designed to encourage practicing clinicians to conduct their own research for the betterment of patients and rheumatology. The 2019 inaugural honoree is Sou-Pan Wu, MD, who will research gout in the Hmong population in Minnesota…

Filed under:AwardsProfessional TopicsResearch Rheum Tagged with:AwardsGaylis AwardNorman B. Gaylis Research Award for Rheumatologists in Community PracticResearchRheumatology Research Foundation

Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

Michele B. Kaufman, PharmD, BCGP  |  May 21, 2019

Results from a Phase 3 study showed ixekizumab significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis in patients…

Filed under:Biologics/DMARDsDrug Updates Tagged with:belimumabFDAixekizumabnon-radiographic axial spondyloarthritissystemic lupus erythematosus (SLE)U.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 124
  • 125
  • 126
  • 127
  • 128
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences